Company Announces Appointments of Samuel Moed and David Fox Chairman Stephen T. Wills Named Executive Chairman
YAVNE, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointments of Mr. Samuel Moed and Mr. David Fox to its Board of Directors to serve until the 2020 annual meeting of shareholders. Stephen T. Wills, MediWound’s Chairman since 2018, was named Executive Chairman.
"We are pleased to welcome Sam and David to our Board of Directors at this important stage of MediWound’s evolution," stated Stephen T. Wills, MediWound’s Executive Chairman. "As highly-respected and seasoned professionals with valuable pharmaceutical and biotechnology industry experience, particularly in strategic and commercial transactions; we look forward to their assistance in guiding our objectives bringing breakthrough medicines in burn and wound treatments through development and towards registration and commercialization."
Mr. Samuel Moed joins the MediWound board having recently retired as an executive from Bristol-Myers Squibb, a global biopharma company focused on innovative therapeutics. In his most recent capacity as Senior Vice President, Corporate Strategy, Mr. Moed led the strategic planning of the company in all major business activities worldwide. His most recent focus has been on the $90 billion acquisition and integration of Celgene by BMS. Previously, Mr. Moed oversaw strategy for BMS’s Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of strategic alliances. Among other positions, he served as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare. Mr. Moed received a BA in history from Columbia University in New York City.
"I am enthusiastic about joining the MediWound Board," stated Mr. Moed. "I look forward to working alongside my fellow Board members and senior management to advance truly innovative drug candidates and help facilitate MediWound’s strategic growth."
Mr. David Fox brings to the MediWound Board decades of leadership and deal experience and insight. Mr. Fox was most recently a partner at Kirkland & Ellis LLP and served as a member of its Global Executive Management Committee until 2019. Prior to joining Kirkland, Mr. Fox was partner with Skadden, Arps, Slate, Meagher & Flom LLP, where he was a member of its top governing committee. Mr. Fox is a director of Israel Discount Bank of New York, a member of the board of directors at the Park Avenue Armory, and a member of the advisory board of New Alternatives for Children, for which he provides crucial support to families caring for medically fragile children. In addition, David is on the board of governors and an honorary fellow of the Hebrew University, Jerusalem.
"I'm excited to join MediWound’s Board and collaborate with other Board members and MediWound’s executive leadership team to contribute to the company's mission of developing and delivering innovative medicines for patients with severe burns and advanced wound care management," said Mr. Fox.
